Ovarian Cancer Genetics

Brittany DeGreef, MS, CGC
Lee Shulman, MD
Cancer Genetics Program
Northwestern Medicine
September 9, 2017
Disclosure

- I serve on the Genetic Counseling Advisory Board for Invitae Laboratories.
Ovarian Cancer

Risk Factors

**Non-Genetic**
- Age
- Nulliparity (never being pregnant)
- Family history of ovarian cancer

**Genetic**
- *BRCA1* or *BRCA2* carrier
- Lynch syndrome (HNPCC)
- Other single gene mutations (rare)
1 out of 72 women will develop ovarian cancer in their lifetime (1.4%)
Ovarian Cancer Risks

Ranges from 5-50%

- General Population: 1.4%
- First degree relative with ovarian cancer: 3-5%
- Two first degree relatives with ovarian cancer: 7%
- Gene Mutation: Ranges from 5-50%
Ovarian Cancer

Sporadic: ~70%
- Cancer occurs by chance or related to environmental factors
- General population cancer risk

Familial: ~20%
- Multiple genes and environmental factors
- Some increase in cancer risk

Hereditary: 5-10%
- Gene mutation is inherited in family
- Significant increased cancer risk
Causes of Hereditary Susceptibility to Ovarian Cancer

Clues for a Hereditary Cancer Syndrome

- Early age of diagnosis
  - Typically diagnosed under the age of 60
- Multiple primary cancers in one individual
  - Such as ovarian cancer and breast cancer
- Individual with ovarian cancer and family history of ovarian and/or breast cancer typically diagnosed under the age of 50
- Multiple generations affected with cancer
- Rare cancers (i.e. male breast cancer)
- Ashkenazi Jewish ancestry
How Cancer Forms

**Sporadic Cancer**

Normal Cell → Accumulate changes or mutations over time → Tumor Development

**Hereditary Cancer**

Predisposed Cell → Accumulate changes or mutations over time → Tumor Development
What are these “genes”?

- Tumor suppressor genes
- Carried by both men and women
- Two copies of every gene in our body (~25,000)

What does a mutation mean?

- One copy of gene can no longer perform normal function of “tumor suppressing”
- Increased risk of cancer
Inheritance

50% chance to pass on the working copy of the gene

50% chance to pass on the non-working copy of the gene
Hereditary Cancer Syndromes

Associated with an Increased Risk for Ovarian Cancer

<table>
<thead>
<tr>
<th>Genes</th>
<th>Hereditary Breast and Ovarian Cancer Syndrome (HBOC)</th>
<th>Lynch Syndrome</th>
<th>Other/Moderate Risk Genes for Ovarian Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA1 and BRCA2</td>
<td>MLH1, MSH2, MSH2, PMS2, EPCAM</td>
<td>BRIP1, RAD51C, RAD51D</td>
<td></td>
</tr>
</tbody>
</table>

| Ovarian Cancer Risk | 20-40% | 10-15% | 5-15% |

<table>
<thead>
<tr>
<th>Other Cancer Risks</th>
<th>Female/Male Breast (50-60%, up to 6%)</th>
<th>Prostate (15%)</th>
<th>Melanoma (5%)</th>
<th>Pancreatic</th>
<th>Colon (up to 70%)</th>
<th>Uterine (40-60%)</th>
<th>Gastric (up to 13%)</th>
<th>Urinary Tract (up to 7%)</th>
<th>Pancreatic (up to 6%)</th>
<th>Unknown?</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Management Recommendations</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Type</td>
<td>Frequency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Breast Exam</td>
<td>Every 6-12 months, beginning at age 25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mammogram</td>
<td>Annually, beginning at age 30*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast MRI</td>
<td>Annually, beginning at age 25*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilateral Mastectomy</td>
<td>Discussed as an option</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salpingectomy-oophorectomy</td>
<td>Breast cancer risk reduction: 90%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ovarian cancer risk reduction: 56%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast cancer risk reduction: 50%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type</td>
<td>Frequency</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>Every 1-2 years beginning at the age of 25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper EGD</td>
<td>Consider every 3-5 years beginning age 30-35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinalysis</td>
<td>Consider annually beginning age 30-35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Abdominal Hysterectomy &amp; Salpingectomy-oophorectomy</td>
<td>Recommended after childbearing years (40s)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Currently no Guidelines

Based on NCCN Guidelines 2017
## Hereditary Cancer Syndromes

### Associated with an Increased Risk for Ovarian Cancer

<table>
<thead>
<tr>
<th>Genes</th>
<th>Hereditary Breast and Ovarian Cancer Syndrome (HBOC)</th>
<th>Lynch Syndrome</th>
<th>Other/Moderate Risk Genes for Ovarian Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BRCA1 and BRCA2</strong></td>
<td><strong>MLH1, MSH2, MSH2, PMS2, EPCAM</strong></td>
<td><strong>BRIP1, RAD51C, RAD51D</strong></td>
<td></td>
</tr>
</tbody>
</table>

| Ovarian Cancer Risk | 20-40% | 10-15% | 5-15% |

<table>
<thead>
<tr>
<th>Other Cancer Risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/Male Breast (50-60%, up to 6%)</td>
</tr>
<tr>
<td>Prostate (15%)</td>
</tr>
<tr>
<td>Melanoma (5%)</td>
</tr>
<tr>
<td>Pancreatic</td>
</tr>
<tr>
<td>Colon (up to 70%)</td>
</tr>
<tr>
<td>Uterine (40-60%)</td>
</tr>
<tr>
<td>Gastric (up to 13%)</td>
</tr>
<tr>
<td>Urinary Tract (up to 7%)</td>
</tr>
<tr>
<td>Pancreatic (up to 6%)</td>
</tr>
<tr>
<td>Unknown?</td>
</tr>
</tbody>
</table>

### Management Recommendations

<table>
<thead>
<tr>
<th>Type</th>
<th>Frequency</th>
<th>Type</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Breast Exam</td>
<td>Every 6-12 months, beginning at age 25</td>
<td>Colonoscopy</td>
<td>Every 1-2 years beginning at the age of 25</td>
</tr>
<tr>
<td>Mammogram</td>
<td>Annually, beginning at age 30*</td>
<td>Upper EGD</td>
<td>Consider every 3-5 years beginning age 30-35</td>
</tr>
<tr>
<td>Breast MRI</td>
<td>Annually, beginning at age 25*</td>
<td>Urinalysis</td>
<td>Consider annually beginning age 30-35</td>
</tr>
<tr>
<td>Bilateral Mastectomy</td>
<td>Discussed as an option</td>
<td>Total Abdominal Hysterectomy &amp; Salpingectomy-oophorectomy</td>
<td>Recommended after childbearing years (40s)</td>
</tr>
<tr>
<td>Salpingectomy-oophorectomy</td>
<td>Breast cancer risk reduction: 90%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ovarian cancer risk reduction: 56%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast cancer risk reduction: 50%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Based on NCCN Guidelines 2017**
# Hereditary Cancer Syndromes

## Associated with an Increased Risk for Ovarian Cancer

<table>
<thead>
<tr>
<th>Genes</th>
<th>Hereditary Breast and Ovarian Cancer Syndrome (HBOC)</th>
<th>Lynch Syndrome</th>
<th>Other/Moderate Risk Genes for Ovarian Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA1 and BRCA2</td>
<td>MLH1, MSH2, MSH2, PMS2, EPCAM</td>
<td>BRIP1, RAD51C, RAD51D</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ovarian Cancer Risk</th>
<th>20-40%</th>
<th>10-15%</th>
<th>5-15%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Cancer Risks</td>
<td>Female/Male Breast (50-60%, up to 6%) Prostate (15%) Melanoma (5%) Pancreatic</td>
<td>Colon (up to 70%) Uterine (40-60%) Gastric (up to 13%) Urinary Tract (up to 7%) Pancreatic (up to 6%)</td>
<td>Unknown?</td>
</tr>
</tbody>
</table>

## Management Recommendations

**Type**
- Clinical Breast Exam
- Mammogram
- Breast MRI
- Bilateral Mastectomy
- Salpingectomy-oophorectomy

**Frequency**
- Every 6-12 months, beginning at age 25
- Annually, beginning at age 30*
- Annually, beginning at age 25*
- Discussed as an option
- Recommended after childbearing years (late 30s-early 40s)
- Ovarian cancer risk reduction: 56%
- Breast cancer risk reduction: 30%

**Type**
- Colonoscopy
- Upper EGD
- Urinalysis
- Total Abdominal Hysterectomy & Salpingectomy-oophorectomy

**Frequency**
- Every 1-2 years beginning at the age of 25
- Consider every 3-5 years beginning age 30-35
- Consider annually beginning age 30-35
- Recommended after childbearing years (40s)

*Currently no Guidelines

Based on NCCN Guidelines 2017
# Hereditary Cancer Syndromes

## Associated with an Increased Risk for Ovarian Cancer

<table>
<thead>
<tr>
<th>Genes</th>
<th>Hereditary Breast and Ovarian Cancer Syndrome (HBOC)</th>
<th>Lynch Syndrome</th>
<th>Other/Moderate Risk Genes for Ovarian Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA1 and BRCA2</td>
<td>MLH1, MSH2, MSH2, PMS2, EPCAM</td>
<td>BRIP1, RAD51C, RAD51D</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ovarian Cancer Risk</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>20-40%</td>
<td>10-15%</td>
<td>5-15%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other Cancer Risks</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/Male Breast (50-60%, up to 6%)</td>
<td>Colon (up to 70%)</td>
<td>Unknown?</td>
</tr>
<tr>
<td>Prostate (15%)</td>
<td>Uterine (40-60%)</td>
<td></td>
</tr>
<tr>
<td>Melanoma (5%)</td>
<td>Gastric (up to 13%)</td>
<td></td>
</tr>
<tr>
<td>Pancreatic</td>
<td>Urinary Tract (up to 7%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pancreatic (up to 6%)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Management Recommendations</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type</strong></td>
<td><strong>Frequency</strong></td>
<td></td>
</tr>
<tr>
<td>Clinical Breast Exam</td>
<td>Every 6-12 months, beginning at age 25</td>
<td></td>
</tr>
<tr>
<td>Mammogram</td>
<td>Annually, beginning at age 30*</td>
<td></td>
</tr>
<tr>
<td>Breast MRI</td>
<td>Annually, beginning at age 25*</td>
<td></td>
</tr>
<tr>
<td>Bilateral Mastectomy</td>
<td>Discussed as an option</td>
<td></td>
</tr>
<tr>
<td>Salpingectomy-oophorectomy</td>
<td>Breast cancer risk reduction: 90%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ovarian cancer risk reduction: 56%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recommended after childbearing years (late 30s-early 40s)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type</th>
<th>Frequency</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Colonoscopy</td>
<td>Every 1-2 years beginning at the age of 25</td>
<td></td>
</tr>
<tr>
<td>Upper EGD</td>
<td>Consider every 3-5 years beginning age 30-35</td>
<td></td>
</tr>
<tr>
<td>Urinalysis</td>
<td>Consider annually beginning age 30-35</td>
<td></td>
</tr>
<tr>
<td>Total Abdominal Hysterectomy &amp; Salpingectomy-oophorectomy</td>
<td>Recommended after childbearing years (40s)</td>
<td></td>
</tr>
</tbody>
</table>

Based on NCCN Guidelines 2017
## Hereditary Cancer Syndromes

**Associated with an Increased Risk for Ovarian Cancer**

<table>
<thead>
<tr>
<th>Genes</th>
<th>Hereditary Breast and Ovarian Cancer Syndrome (HBOC)</th>
<th>Lynch Syndrome</th>
<th>Other/Moderate Risk Genes for Ovarian Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BRCA1 and BRCA2</strong></td>
<td></td>
<td><strong>MLH1, MSH2, MSH2, PMS2, EPCAM</strong></td>
<td><strong>BRIP1, RAD51C, RAD51D</strong></td>
</tr>
<tr>
<td><strong>Ovarian Cancer Risk</strong></td>
<td>20-40%</td>
<td>10-15%</td>
<td>5-15%</td>
</tr>
<tr>
<td><strong>Other Cancer Risks</strong></td>
<td>Female/Male Breast (50-60%, up to 6%)</td>
<td>Colon (up to 70%)</td>
<td>Colon (up to 70%)</td>
</tr>
<tr>
<td></td>
<td>Prostate (15%)</td>
<td>Uterine (40-60%)</td>
<td>Unknown?</td>
</tr>
<tr>
<td></td>
<td>Melanoma (5%)</td>
<td>Gastric (up to 13%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pancreatic</td>
<td>Urinary Tract (up to 7%)</td>
<td></td>
</tr>
</tbody>
</table>

### Management Recommendations

- **Clinical Breast Exam**: Every 6-12 months, beginning at age 25
- **Mammogram**: Annually, beginning at age 30*
- **Breast MRI**: Annually, beginning at age 25*
- **Bilateral Mastectomy**: Discussed as an option Breast cancer risk reduction: 90%
- **Salpingectomy-oophorectomy**: Recommended after childbearing years (late 30s-early 40s) Ovarian cancer risk reduction: 96% Breast cancer risk reduction: 50%

<table>
<thead>
<tr>
<th>Type</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colonoscopy</td>
<td>Every 1-2 years beginning at the age of 25</td>
</tr>
<tr>
<td>Upper EGD</td>
<td>Consider every 3-5 years beginning age 30-35</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>Consider annually beginning age 30-35</td>
</tr>
<tr>
<td>Total Abdominal Hysterectomy &amp; Salpingectomy-oophorectomy</td>
<td>Recommended after childbearing years (40s)</td>
</tr>
</tbody>
</table>
Ovarian Cancer Risk Reduction

HBOC and Lynch Syndrome

• Birth control pills
  – 5 years of use: 27% reduction
  – 15 years of use: 60% reduction
• First full-term pregnancy < age 25; number of pregnancies
• Breast-feeding
• Bilateral tubal ligation/hysterectomy
• Prophylactic oophorectomy
  – Risk of primary peritoneal cancer remains
Ovarian Cancer Risk Reduction

*BRIP1, RAD51C, RAD51D*

• Ovarian cancer
  – Approximately 15% lifetime risk of ovarian cancer

• Currently no established guidelines
  – Recommend risk reducing oophorectomy following natural menopause

• Other cancer risks?
  – TBD
Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction

Michael J. Callahan, Christopher P. Crum, Fabiola Medeiros, David W. Kindelberger, Julia A. Elvin, Judy E. Garber, Colleen M. Feltmate, Ross S. Berkowitz, and Michael G. Muto


Tubal ligation and the risk of ovarian cancer: review and meta-analysis

D. Cibula 1,* M. Widschwendter 2, O. Májek 3, and L. Dusek 3
• Recent studies have suggested majority of ovarian cancer begins in fallopian tubes in women with BRCA1/2 mutations (~80%)

• **RESEARCH** currently ongoing to evaluate for removal of fallopian tubes first
  – Delays surgical menopause while *hopefully* reducing ovarian cancer risk
  – Remove ovaries few years later

• **NOT STANDARD OF CARE, only being performed on research basis at this point**
What if I already had negative *BRCA1* and *BRCA2* testing?

AGCTGTCTACTCAAGTCACTGCAGTCACTGCACTGCAAGTCACTGCAAGTCACTGCACTGCACTGCACTG

- **Sequencing Analysis**
  - Reads through each letter one by one
  - Picks up approximately 95% of mutations in *BRCA1/2*
What if I already had negative *BRCA1* and *BRCA2* testing?

AGCTGTCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTCACTGCAAGTC
What if I already had negative *BRCA1* and *BRCA2* testing?

AGCTGTGTTCAAGTCACTGCACTGCAGTCAGTACGTGACCGTGACAGTCAATTGCACCGTGACAGTCACT
TGCTGTGTTCAAGTCACTGCACTGCAGTCAGTACGTGACCGTGACAGTCAATTGCACCGTGACAGTCACT
What if I already had negative *BRCA1* and *BRCA2* testing?
What if I already had negative *BRCA1* and *BRCA2* testing?

AGCTGTTCAGTCACTGCAGTCAGGTACGTTTGCAACCAGTGAATCTCAAGTCACTGCAGTCAGTCAGTACGTTGCACCGTGACAGTCAAAGCTGTCAAGTCAGTCACTGCAGTCAGTCAGTACGTTGCACCGTGACAGTCAATTGCACCGTGACAGTCACGTGACT

- **Deletion/Duplication Analysis**
  - Looks for large amounts of letters that are missing or added
  - Picks up approximately 5% of mutations in *BRCA1* or *BRCA2*
What if I already had negative BRCA1 and BRCA2 testing? Are there other genes related to ovarian cancer?

• Gene panels...
  – Includes more than one gene related to specific indication such as ovarian cancer
    • High risk genes: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
    • Moderate risk genes: BRIP1, RAD51C, RAD51D
    • And many more...

• Changing yearly, even monthly
Genetic Testing

- Multi-Gene Panel vs Single Gene Testing
  - Multiple cases of cancer within a family
  - Isolated case of ovarian cancer diagnosed at any age
  - Identified familial mutation

- Genetic Testing Results:
  - No Mutation Found
  - Pathogenic
  - Variant of uncertain significance (VUS) – inconclusive
All of my genetic testing was negative, now what?

• Management based on personal and family history of cancer

• First degree female relatives (daughters, sisters, mothers):
  • Consider ovarian cancer screening as part of a research protocol
  • Northwestern Ovarian Cancer Detection and Prevention Program
  • Trans-vaginal ultrasound and CA-125 level

• Consult with physicians/genetic counselors periodically for updated genetic testing and recommendations
Benefits of Genetic Testing

- Provide an explanation for your personal or family history of cancer
- Evaluate your risk of developing future cancers
- Make informed medical decisions, including treatment, surveillance, and preventive options
- Potential use of other chemotherapy options
  - PARP inhibitors for BRCA1/2 individuals
- Qualify you for participation in clinical trials or research studies
- Identify other at-risk relatives for whom genetic testing is recommended
- Always changing and evolving – periodically check-in with genetics
Drawbacks to Genetic Testing

- Will results make a difference in my care?
- May be inconclusive
- Risk for developing cancer not always established
- What interventions are available?
- Psychosocial implications
Tumor DNA Testing

- Uses next generation sequencing (many, many genes)
- Testing performed to look for DNA mutations *within* cancer cells/tumor only
  - Different from genetic testing (testing we just reviewed)
- Typically performed to look for treatment targets or response to treatment
- Incidentally can find a genetic mutation that you were born with (inherited mutation)
- “New-er” so work in progress and rapidly evolving... (stay tuned)
How Cancer Forms

Sporadic Cancer

Normal Cell → Accumulate changes or mutations over time → Tumor Development

Hereditary Cancer

Predisposed Cell → Accumulate changes or mutations over time → Tumor Development
How Cancer Forms

Sporadic Cancer

1. Normal Cell
2. Accumulate changes or mutations over time
3. Tumor Development

Hereditary Cancer

1. Predisposed Cell
2. Accumulate changes or mutations over time
3. Tumor Development
How Cancer Forms

**Sporadic Cancer**

- Normal Cell
- Accumulate changes or mutations over time
- Tumor Development

**Hereditary Cancer**

- Predisposed Cell
- Accumulate changes or mutations over time
- Tumor Development
Other Considerations...

- Genetic Information Nondiscrimination Act (GINA) passed in 2008
- Family planning options
- Openness or willingness to communicate with family members
  - Family letter
- Psychosocial Implications
- Patient advocacy groups
Dear family:

I am writing this letter to inform you that I recently had genetic testing and was diagnosed with a condition called hereditary breast and ovarian cancer syndrome (HBOC) which affects families. This letter contains information about HBOC, how it might affect you, and how to find out if you have this condition also.

People who have HBOC have increased cancer risks. Specifically women have increased risks for breast cancer and ovarian cancer, and men have increased risks for prostate cancer and male breast cancer. It is recommended that anyone with HBOC have increased screening for these cancers which helps detect cancers earlier when they are more easily treated, and in some cases, prevent them altogether.

Hereditary breast and ovarian cancer syndrome is caused by a mutation in a gene that can be inherited in families. The specific mutation identified in me was in the BRCA* gene (***). Genetic testing is available for you to see if you carry this same mutation. You can take this letter to your doctor, or contact the genetics team at Northwestern Cancer Genetics to discuss this further and find out how to get tested in your area. You can also find a genetic counselor near you by going to the following website: www.nsgc.org and using the “Find a Genetic Counselor” tool.

If you or your doctors have additional questions, the Northwestern Cancer Genetics team would be happy to discuss this further. You can reach a member of the Cancer Genetics Team at 312-472-0518 or 312-472-0523.

Sincerely,
Find a Genetic Counselor Near you
http://www.aboutgeneticcounselors.com/
Thank You

Email: Brittany.DeGreef@nm.org
Scheduling: (312) 695-0320